Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 05.

323P - Development of a model to predict PD-L1 expression in pulmonary squamous cell carcinoma based on CT imaging features

Date

03 Dec 2022

Session

Poster viewing 05.

Topics

Radiological Imaging

Tumour Site

Thoracic Malignancies

Presenters

Yun Kyoung Shin

Citation

Annals of Oncology (2022) 33 (suppl_9): S1560-S1597. 10.1016/annonc/annonc1134

Authors

Y.K. Shin, J. Im, H.J. Yoon

Author affiliations

  • Radiology, Seoul Veterans Hospital, 134-791 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 323P

Background

An immune checkpoint inhibitor that targets programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) has recently been discovered, and it demonstrates superior treatment efficacy and improves prognosis over existing chemotherapeutic agents in non-small cell lung cancer. Several studies have demonstrated correlations between computed tomography (CT) imaging features and PD-L1 expression in lung adenocarcinoma (ADC). However, there have been few studies on the association between lung squamous cell carcinoma (SCC) and CT findings. Thus, we aimed to identify the associations between CT findings and PD-L1 expression in SCC and to develop models to predict the expression of PD-L1 in lung SCC using CT.

Methods

This retrospective study included 99 patients diagnosed with SCC and pretreatment CT images and PD-L1 expression assay results. We performed CT feature analysis of the tumors using pretreatment CT images. We then constructed multiple logistic regression models to predict PD-L1 positivity in the total patient group and in 41 advanced-stage (≥ stage IIIB) patients. To identify predictive efficiency, areas under the receiver operating characteristic curves (AUCs) of each model were calculated.

Results

Among the 99 patients, 68 (68.7%) were PD-L1-positive and among the 41 advanced patients, 30 (73.2%) were PD-L1-positive. For the total patient group, the AUC of the ‘total significant features model’ (tumor stage, primary tumor size, pleural nodularity and lung metastasis) was 0.637, and that of the ‘selected feature model’ (pleural nodularity) was 0.556. For advanced-stage patients, the AUC of the selected feature model (primary tumor size, central distribution, pleural nodularity, and pulmonary oligometastases) was 0.882. Among these factors, the presence of pleural nodularity and pulmonary oligometastases had high odds ratios (4.11 and 9.60, respectively).

Conclusions

Our model was able to predict PD-L1 expression in patients with advanced-stage SCC of the lung, and the presence of pleural nodularity and pulmonary oligometastases were notable predictive CT features of PD-L1. A predictive model based on CT features may facilitate non-invasive assessment of PD-L1 expression.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

This study was supported by a VHS Medical Center Research Grant, Republic of Korea (grant number: VHSMC 21007).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.